Shandong Pharmaceutical Financials
| 600529 Stock | 24.52 0.31 1.28% |
| Current Value | Last Year | Change From Last Year | 10 Year Trend | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Operating Income | 943.8 M | 898.9 M |
|
|
Shandong | Select Account or Indicator |
Understanding current and past Shandong Pharmaceutical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Shandong Pharmaceutical's financial statements are interrelated, with each one affecting the others. For example, an increase in Shandong Pharmaceutical's assets may result in an increase in income on the income statement.
Please note, the presentation of Shandong Pharmaceutical's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Shandong Pharmaceutical's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Shandong Pharmaceutical's management manipulating its earnings.
Shandong Pharmaceutical Stock Summary
Shandong Pharmaceutical competes with Zhuhai Comleader, Focus Media, Northking Information, YLZ Information, and Dawning Information. Shandong Pharmaceutical is entity of China. It is traded as Stock on SHG exchange.Specialization | Consumer Cyclical, Health Care Equipment & Services |
| Instrument | China Stock View All |
| Exchange | Shanghai Stock Exchange |
| ISIN | CNE000001BG9 |
| Business Address | Yaobo Road, Zibo, |
| Sector | Health Care Equipment & Supplies |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.pharmglass.com |
| Phone | 86 53 3325 9167 |
You should never invest in Shandong Pharmaceutical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Shandong Stock, because this is throwing your money away. Analyzing the key information contained in Shandong Pharmaceutical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Shandong Pharmaceutical Key Financial Ratios
Shandong Pharmaceutical's financial ratios allow both analysts and investors to convert raw data from Shandong Pharmaceutical's financial statements into concise, actionable information that can be used to evaluate the performance of Shandong Pharmaceutical over time and compare it to other companies across industries.| Revenue | 4.98 B | ||||
| Gross Profit | 1.12 B | ||||
| EBITDA | 1.35 B | ||||
| Net Income | 775.8 M | ||||
| Total Asset | 9.32 B |
Shandong Pharmaceutical Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 5.2B | 5.6B | 6.4B | 8.8B | 9.3B | 9.8B | |
| Other Current Liab | 175.9M | 156.5M | 117.6M | 324.5M | 69.9M | 131.4M | |
| Retained Earnings | 2.3B | 2.7B | 3.1B | 3.5B | 3.6B | 3.8B | |
| Accounts Payable | 996.2M | 995.8M | 1.4B | 1.4B | 1.4B | 1.5B | |
| Cash | 1.1B | 1.1B | 885.0M | 1.4B | 1.5B | 1.5B | |
| Net Receivables | 713.8M | 640.8M | 764.4M | 871.7M | 970.1M | 622.7M | |
| Inventory | 679.4M | 749.2M | 877.7M | 1.2B | 1.1B | 1.1B | |
| Other Current Assets | 88.3M | 82.5M | 62.0M | 104.6M | 35.0M | 33.3M | |
| Total Liab | 1.3B | 1.4B | 1.7B | 1.8B | 1.8B | 897.5M | |
| Intangible Assets | 171.8M | 203.3M | 198.4M | 260.4M | 253.7M | 266.3M | |
| Other Assets | 64.4M | 161.3M | 319.4M | 381.9M | 439.2M | 461.2M | |
| Other Liab | 49.7M | 60.0M | 60.0M | 58.9M | 67.8M | 71.2M | |
| Net Tangible Assets | 3.7B | 4.1B | 4.5B | 6.7B | 7.7B | 4.2B | |
| Total Current Assets | 3.0B | 3.1B | 3.3B | 5.3B | 5.5B | 3.7B | |
| Net Invested Capital | 3.9B | 4.3B | 4.7B | 7.0B | 7.5B | 5.4B | |
| Net Working Capital | 1.8B | 1.8B | 1.7B | 3.6B | 3.8B | 2.6B |
Shandong Pharmaceutical Key Income Statement Accounts
An income statement is very similar to a cash flow statement, but instead of showing net revenue minus expenses, it only includes earnings before interest and taxes (EBIT). This number does not have all of the same line items that are on a cash flow statement, but it leaves out non-cash expenses like depreciation and amortization. For example, if you bought $100 worth of goods from Walmart (WMT) using your debit card that has an interest rate of 20%, then paid off the balance at the end of the month with a credit card that charges 30% interest, you would have an income statement showing EBIT of $80 because your expenses are lower than the amount that went into your pocket.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Interest Expense | 1.7M | 2.3M | 2.8M | 2.6M | 226.8K | 215.5K | |
| Total Revenue | 3.0B | 3.4B | 3.9B | 4.2B | 5.0B | 5.2B | |
| Operating Income | 564.7M | 718.5M | 732.2M | 707.2M | 898.9M | 943.8M | |
| Cost Of Revenue | 1.9B | 2.3B | 2.7B | 3.1B | 3.6B | 3.8B | |
| Income Before Tax | 546.0M | 653.5M | 688.7M | 708.1M | 910.8M | 956.4M | |
| Net Income | 458.7M | 564.4M | 591.1M | 618.3M | 775.8M | 814.6M | |
| Income Tax Expense | 87.4M | 89.0M | 97.6M | 89.8M | 103.2M | 52.4M | |
| Research Development | 132.0M | 141.3M | 136.8M | 138.9M | 137.9M | 103.4M | |
| Gross Profit | 1.1B | 1.1B | 1.1B | 1.1B | 1.4B | 1.1B | |
| Ebit | 526.8M | 661.4M | 678.8M | 707.2M | 813.3M | 532.3M | |
| Tax Provision | 87.4M | 89.0M | 97.6M | 89.8M | 135.0M | 91.6M | |
| Net Interest Income | 10.9M | 13.5M | 10.8M | 12.5M | 22.7M | 23.8M | |
| Interest Income | 11.8M | 14.7M | 10.9M | 12.2M | 25.7M | 27.0M | |
| Ebitda | 713.4M | 869.1M | 926.6M | 1.0B | 1.2B | 831.8M |
Shandong Pharmaceutical Key Cash Accounts
Cash flow analysis captures how much money flows into and out of Shandong Pharmaceutical. It measures of how well Shandong is doing because it can show the actual money that comes into and out of the Company from sales instead of measuring expenses against revenue to determine earnings. You have to read the cash flow statement in three sections. The first section shows how much money Shandong Pharmaceutical brought in, usually known as net revenue or sales. This is different from earnings because it does not include expenses when determining net revenue for use on this part of the cash flow statement. Next, are operating activities, which show how much money Shandong had leftover after paying for its expenses. This number can be calculated in two ways: by subtracting the total of all operating expenses from net revenue or by adding up changes to cash and other assets or liabilities on this part of the statement. The third section is about investing activities, which shows what Shandong Pharmaceutical has done with the money that it received from the sale of assets or what it spent to acquire new ones. This section can be broken down into two parts: investing in existing businesses (in other words, buying more stock) and investing in non-business activities like paying off debt or making acquisitions.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Capital Expenditures | 591.7M | 535.2M | 809.3M | 710.7M | 671.5M | 705.1M | |
| Net Income | 458.7M | 564.4M | 591.1M | 618.3M | 775.8M | 814.6M | |
| Dividends Paid | 57.0M | 100.7M | 127.5M | 178.5M | 199.1M | 209.0M | |
| Change To Inventory | (121.9M) | (99.5M) | (155.1M) | (355.4M) | 125.9M | 132.2M | |
| Investments | 328M | 230M | (74M) | (796M) | (744.6M) | (707.3M) | |
| Change In Cash | 249.2M | 86.6M | (301.9M) | 452.4M | 126.5M | 92.5M | |
| Depreciation | 169.1M | 217.9M | 240.3M | 295.2M | 325.1M | 221.7M | |
| Change To Netincome | 19.7M | 77.5M | 65.1M | 28.0M | 32.2M | 46.8M | |
| End Period Cash Flow | 923.3M | 1.0B | 708.0M | 1.2B | 1.3B | 1.1B | |
| Free Cash Flow | 7.4M | 30.8M | (58.8M) | (458.3M) | 376.5M | 395.3M | |
| Other Non Cash Items | (6.1M) | 14.9M | 6.6M | (20.1M) | (9.6M) | (9.1M) |
Shandong Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Shandong Pharmaceutical's current stock value. Our valuation model uses many indicators to compare Shandong Pharmaceutical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Shandong Pharmaceutical competition to find correlations between indicators driving Shandong Pharmaceutical's intrinsic value. More Info.Shandong Pharmaceutical Glass is number one stock in return on equity category among its peers. It also is number one stock in return on asset category among its peers reporting about 0.57 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for Shandong Pharmaceutical Glass is roughly 1.76 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Shandong Pharmaceutical by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Shandong Pharmaceutical's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Shandong Pharmaceutical Systematic Risk
Shandong Pharmaceutical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Shandong Pharmaceutical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The function did not generate any output. Please change time horizon or modify your input parameters. The output start index for this execution was one with a total number of output elements of sixty. The Beta measures systematic risk based on how returns on Shandong Pharmaceutical correlated with the market. If Beta is less than 0 Shandong Pharmaceutical generally moves in the opposite direction as compared to the market. If Shandong Pharmaceutical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Shandong Pharmaceutical is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Shandong Pharmaceutical is generally in the same direction as the market. If Beta > 1 Shandong Pharmaceutical moves generally in the same direction as, but more than the movement of the benchmark.
Shandong Pharmaceutical Glass Total Assets Over Time
Shandong Pharmaceutical December 1, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Shandong Pharmaceutical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Shandong Pharmaceutical Glass. We use our internally-developed statistical techniques to arrive at the intrinsic value of Shandong Pharmaceutical Glass based on widely used predictive technical indicators. In general, we focus on analyzing Shandong Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Shandong Pharmaceutical's daily price indicators and compare them against related drivers.
| Downside Deviation | 2.24 | |||
| Information Ratio | (0) | |||
| Maximum Drawdown | 16.01 | |||
| Value At Risk | (3.84) | |||
| Potential Upside | 3.43 |
Complementary Tools for Shandong Stock analysis
When running Shandong Pharmaceutical's price analysis, check to measure Shandong Pharmaceutical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Shandong Pharmaceutical is operating at the current time. Most of Shandong Pharmaceutical's value examination focuses on studying past and present price action to predict the probability of Shandong Pharmaceutical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Shandong Pharmaceutical's price. Additionally, you may evaluate how the addition of Shandong Pharmaceutical to your portfolios can decrease your overall portfolio volatility.
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| Technical Analysis Check basic technical indicators and analysis based on most latest market data | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Transaction History View history of all your transactions and understand their impact on performance | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes |